99.2% Pure Vandetanib Powder CAS 443913-73-3 Caprelsa for Anti-Cancer Drug--Chongqing Saipu Nasi Technology Co., Ltd

99.2% Pure Vandetanib Powder CAS 443913-73-3 Caprelsa for Anti-Cancer Drug

Basic Info.

Product name:Vandetanib

Other name:Caprelsa

CAS No:443913-73-3

Molecular formula:C22H24BrFN4O2

Molecular weight:475.35

EINECS:N/A

Appearance: White crystalline powder

Catalogue:Pharmaceutical materials.

HS code: 3001200010

Reference FOB Price:$1/g

MOQ:10g

Shelf life:2 years

Specification:ISO9001,USP,BP,GMP

Trade Mark:CQSP

Port:Shenzhen/Shanghai,China

Production Capacity:5000kg/month

Shipping: DHL, EMS, FedEx, UPS

More details pls contact:Whatapp:86 13048470428

Skype/E-mail : summer at chembj.com

What is Vandetanib?

Vandetanib is a treatment for advanced medullary thyroid cancer. You may also have it as part of a clinical trial for other types of cancer.

Vandetanib is a type of biological therapy. It is a cancer growth blocker, which stops signals (chemical messengers) that cancer cells use to divide and grow.

Vandetanib benefits

Vandetanib is an orally available receptor tyrosine kinase (RTK) inhibitor, which blocks both the vascular endothelial growth factor (VEGF) RTK and the Epidermal Growth Factor (EGF) RTK. Blockade of the VEGF receptors limits the growth of new blood vessels, which are vital to supporting the growth of tumors. Without sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth.

Vandetanib is specifically indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Vandetanib is supplied as a tablet for oral administration. The recommended daily dose is 300 mg of vandetanib taken orally, with or wothout food. Vandetanib treatment should be continued until patients are no longer benefiting from treatment or an unacceptable toxicity occurs.

Vandetanib Clinical Results

The FDA approval of Vandetanib was based on a double-blind, placebo-controlled study in 331 subjects with unresectable locally advanced or metastatic medullary thyroid cancer. The subjects received vandetanib 300 mg or placebo. The primary objective was demonstration of improvement in progression-free survival (PFS) with vandetanib compared to placebo. Other endpoints included evaluation of overall survival and overall objective response rate (ORR). The result of the PFS analysis, based on the central review RECIST assessment, showed a statistically significant improvement in PFS for subjects randomized to vandetanib (p<0.0001). Analyses in the subgroups of subjects who were symptomatic or had progressed within six months prior to their enrollment showed similar PFS results. At the time of the primary analysis of PFS, 15% of the subjects had died and there was no significant difference in overall survival between the two treatment groups. The overall objective response rate (ORR) for subjects randomized to vandetanib was 44% compared to 1% for subjects randomized to placebo. All objective responses were partial responses.

Other Pharmaceutical Raw Material

NO.1 Noopept CAS:157115-85-0

NO.2 Piracetam CAS:7491-74-9

NO.3 Idebenone CAS:58186-27-9

NO.4 phenylpiracetam CAS:77472-70-9

NO.5 Pramiracetam CAS:68497-62-1

NO.6 Rivastigmine CAS:123441-03-2

NO.7 Coluracetam CAS:135463-81-9

NO.8 Entacapone CAS:130929-57-6

NO.9 Oxiracetam CAS:62613-82-5

NO.10 Aniracetam CAS:72432-10-1

NO.11 Donepezil CAS:120014-06-4